UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook

Sep.18
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.

Key Points

  • Supreme continues to expect FY27 trading to be in line with market expectations; analyst consensus immediately before its latest update stood at £302.1 million of revenue and £39.6 million of adjusted EBITDA.
  • The UK's Vaping Products Duty starts October 1 at a flat £2.20 per 10ml of vaping liquid.
  • Supreme has publicly supported a more regulated and compliant vaping market and says the new regime could contribute to market consolidation.
  • Supreme's Vaping revenue increased 15% to £148.1 million in FY26, while its Manchester facility produces around 70 million 10ml e-liquid bottles annually.

2Firsts

September 18, 2026

UK-listed consumer goods group Supreme plc said in a September 17 trading update that it continues to expect results for the year ending March 31, 2027, to meet market expectations, less than two weeks before the UK's Vaping Products Duty takes effect.

Supreme also maintained a comparatively positive stance toward the new tax and compliance framework, saying it supports the government's objective of creating a more regulated and compliant vaping market.

In its FY26 results, the company went further, saying it expected market consolidation following the introduction of the duty and that smaller competitors with less financial and operational capacity could face a significant compliance burden.

Analyst consensus immediately before the latest announcement stood at £302.1 million of FY27 revenue and £39.6 million of adjusted EBITDA. Supreme said trading had started the financial year in line with expectations after investing almost £5 million in its brands so far this year.

Supreme Sees Scope for Market Consolidation

The UK's Vaping Products Duty takes effect on October 1, 2026.

Under HM Revenue & Customs rules, vaping liquid within the scope of the duty will be taxed at a flat rate of £2.20 per 10ml, or £0.22 per millilitre, regardless of whether it contains nicotine.

At that rate, a 10ml bottle carries £2.20 in duty and a 2ml pod carries £0.44. Supreme noted that a two-pack of 2ml pods would therefore attract £0.88 in duty, before VAT.

Rather than focusing solely on the additional cost, Supreme has described the regime as a potential business opportunity.

The company said its contract-manufacturing activity in the 10ml e-liquid segment has been growing and expects that trend could accelerate as smaller manufacturers face greater operational complexity under VPD.

Supreme has said its financial resources, manufacturing platform and compliance capabilities could allow it to gain market share as the sector consolidates.

Those are management expectations. VPD has yet to take effect, and its eventual impact on company exits, market shares and consumer demand has not yet been established by post-implementation market data.

Vaping Revenue Rose 15% in FY26

Vaping remains Supreme's largest operating division.

For the year ended March 31, 2026, Vaping revenue increased by £19.1 million, or 15%, to £148.1 million from £129.0 million a year earlier. Supreme said the growth was entirely organic, supported by expanded distribution of third-party brands including Hayati and IVG, entry into Spain and the rollout of pod devices following the UK's disposable vape ban.

The UK ban on the sale and supply of disposable vapes took effect on June 1, 2025. Supreme said its core 10ml e-liquid operation continued to see steady demand during FY26.

Its Manchester manufacturing facility produces approximately 70 million 10ml e-liquid bottles annually.

At group level, FY26 revenue rose 17% to £270.2 million. Adjusted EBITDA was broadly flat at £40.6 million, compared with £40.5 million a year earlier, while adjusted net cash increased to £7.5 million from £1.2 million.

88Vape Retains Value Positioning

Chief Executive Sandy Chadha said Supreme expects its 88Vape brand, which has long been positioned around value, to continue appealing to existing and new consumers as the new pricing regime takes effect.

Supreme did not disclose post-VPD retail pricing for 88Vape in its latest trading update.

Because the duty is levied at the same absolute rate per millilitre across products, vaping liquids of the same volume carry the same VPD liability regardless of their retail price. Supreme views 88Vape's value positioning as one element of its response to the new pricing environment, although any shift by consumers toward lower-priced products remains a company expectation rather than an observed post-tax market outcome.

Supreme operates across three divisions: Vaping, Drinks & Wellness, and Electricals & Household. The company says it has more than 3,000 active business accounts serving around 55,000 retail outlets.

Follow 2Firsts for timely updates on global tobacco and nicotine industry developments, corporate strategy and market trends.

Cover Image: TheBusinessDesk


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia’s tobacco excise debate is increasingly exposing differences within the governing Labor Party. New South Wales Labor Premier Chris Minns reaffirmed on September 8 that he supports reducing tobacco excise, arguing that current tax settings are pushing consumers toward cheaper black-market cigarettes. Federal Health Minister Mark Butler continues to oppose an excise cut, while Treasurer Jim Chalmers and Assistant Treasurer Daniel Mulino have recently stopped short of ruling out future changes. The divergence follows the opposition Coalition’s proposal to cut tobacco excise by 80%.
Sep.08
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
The UK’s Vaping Products Duty (VPD), scheduled to take effect in October 2026, is prompting retailers to assess how different vape categories may be affected. UK retailer Vape HQ has estimated potential price changes under the new volume-based tax system, showing that 100ml shortfill e-liquids could see prices rise from around £12.99 to £39.39, a 203% increase, while 2ml prefilled pod vape kits could rise from £5.99 to £6.52, an increase of about 9%. The estimates highlight how a volume-based tax structure creates uneven cost impacts across product categories.
Aug.19